Physician profile
Giovanni Infusino
NPI 1447416821
$525,802.59
in general payments reported to CMS, 2019-2025
22 companies · $217K in 2025
The $217K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $282 · 2021: $20.00 · 2022: $2,304 · 2023: $105K · 2024: $200K · 2025: $217K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $441K · Travel and Lodging: $43K · Food and Beverage: $30K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $441,108.50 |
| Travel and Lodging | $43,250.78 |
| Food and Beverage | $29,741.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $523,408.40 | 2022-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Astrazeneca Pharmaceuticals Lp | $446.10 | 2019-2020 | |
| Ethicon INC. | $328.57 | 2022 | |
| Pulmonx Corporation | $240.55 | 2022-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.97 | 2019-2022 | |
| Galvanize Therapeutics, INC | $184.74 | 2025 | Aliya System |
| Astellas Pharma US INC | $164.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $155.62 | 2019-2024 | Nucala |
| Grifols USA, LLC | $118.83 | 2019-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $113.41 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $102.60 | 2019 | |
| Inogen, INC. | $53.37 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen At Home Stationary Concentrator |
| Ceribell, INC. | $50.94 | 2024 | Pocket Eeg Device |
| Fisher & Paykel Healthcare INC | $42.78 | 2023-2024 | Fisher & Paykel Healthcare |
| Medtronic USA, INC. | $41.02 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.58 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $30.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.73 | 2023 | Dupixent |
| Amgen INC. | $21.01 | 2025 | Tezspire |
| United Therapeutics Corporation | $20.00 | 2021 | |
| Veran Medical Technologies, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giovanni Infusino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.